To date, real-world data on the cardioprotective effects and arrhythmia prevention of SGLT2i are mainly about diabetic patients, given that SGLT2-i prescription was only recently extended to non-diabetic patients. This evidence concerns the gene SLC5A2 and cardiac arrhythmia.